Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
28.67 EUR | -0.84% | +2.60% | -14.48% |
04:08pm | Bayer's OcuClick Secures Approval from European Medicines Agency | MT |
02:39pm | BAYER AG : UBS sticks Neutral | ZD |
Projected Income Statement: Bayer AG
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 43,545 | 41,400 | 44,081 | 50,739 | 47,637 | 47,012 | 47,675 | 48,402 |
Change | - | -4.93% | 6.48% | 15.1% | -6.11% | -1.31% | 1.41% | 1.52% |
EBITDA 1 | 11,503 | 11,461 | 11,179 | 13,513 | 11,706 | 10,439 | 10,758 | 10,916 |
Change | - | -0.37% | -2.46% | 20.88% | -13.37% | -10.82% | 3.05% | 1.48% |
EBIT 1 | 7,007 | 7,095 | 7,295 | 9,257 | 7,589 | 6,598 | 6,876 | 7,023 |
Change | - | 1.26% | 2.82% | 26.9% | -18.02% | -13.06% | 4.21% | 2.14% |
Interest Paid 1 | -1,309 | -1,081 | -1,307 | -2,342 | -2,233 | -2,166 | -2,057 | -1,892 |
Earnings before Tax (EBT) 1 | 2,880 | -17,250 | 2,046 | 4,670 | -1,621 | 3,185 | 3,890 | 4,224 |
Change | - | - | - | 128.25% | - | - | 22.13% | 8.59% |
Net income 1 | 4,091 | -10,495 | 1,000 | 4,150 | -2,941 | 2,277 | 3,015 | 3,426 |
Change | - | - | - | 315% | - | - | 32.44% | 13.62% |
Announcement Date | 27/02/20 | 25/02/21 | 01/03/22 | 28/02/23 | 05/03/24 | - | - | - |
Forecast Balance Sheet: Bayer AG
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt 1 | 34,068 | 37,575 | 32,966 | 31,273 | 34,263 | 33,883 | 30,441 | 26,975 |
Change | - | 10.29% | -12.27% | -5.14% | 9.56% | -1.11% | -10.16% | -11.39% |
Announcement Date | 27/02/20 | 25/02/21 | 01/03/22 | 28/02/23 | 05/03/24 | - | - | - |
Cash Flow Forecast: Bayer AG
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
CAPEX 1 | 2,650 | 2,418 | 2,611 | 2,949 | 2,751 | 2,806 | 2,937 | 2,971 |
Change | - | -8.75% | 7.98% | 12.95% | -6.71% | 2.01% | 4.66% | 1.15% |
Free Cash Flow (FCF) 1 | 5,557 | 2,485 | 2,478 | 4,144 | 2,366 | 3,290 | 4,208 | 3,898 |
Change | - | -55.28% | -0.28% | 67.23% | -42.91% | 39.07% | 27.89% | -7.36% |
Announcement Date | 27/02/20 | 25/02/21 | 01/03/22 | 28/02/23 | 05/03/24 | - | - | - |
Forecast Financial Ratios: Bayer AG
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Profitability | ||||||||
EBITDA Margin (%) | 26.42% | 27.68% | 25.36% | 26.63% | 24.57% | 22.21% | 22.56% | 22.55% |
EBIT Margin (%) | 16.09% | 17.14% | 16.55% | 18.24% | 15.93% | 14.03% | 14.42% | 14.51% |
EBT Margin (%) | 6.61% | -41.67% | 4.64% | 9.2% | -3.4% | 6.78% | 8.16% | 8.73% |
Net margin (%) | 9.39% | -25.35% | 2.27% | 8.18% | -6.17% | 4.84% | 6.32% | 7.08% |
FCF margin (%) | 12.76% | 6% | 5.62% | 8.17% | 4.97% | 7% | 8.83% | 8.05% |
FCF / Net Income (%) | 135.83% | -23.68% | 247.8% | 99.86% | -80.45% | 144.52% | 139.55% | 113.78% |
Profitability | ||||||||
ROA | 3.23% | -8.63% | 0.84% | 3.39% | -2.44% | 0.54% | 1.56% | 2.62% |
ROE | 13.47% | 16.15% | 20.14% | 8.65% | 17.52% | 14.67% | 14.5% | 13.54% |
Financial Health | ||||||||
Leverage (Debt/EBITDA) | 2.96x | 3.28x | 2.95x | 2.31x | 2.93x | 3.25x | 2.83x | 2.47x |
Debt / Free cash flow | 6.13x | 15.12x | 13.3x | 7.55x | 14.48x | 10.3x | 7.23x | 6.92x |
Capital Intensity | ||||||||
CAPEX / Current Assets (%) | 6.09% | 5.84% | 5.92% | 5.81% | 5.77% | 5.97% | 6.16% | 6.14% |
CAPEX / EBITDA (%) | 23.04% | 21.1% | 23.36% | 21.82% | 23.5% | 26.88% | 27.3% | 27.22% |
CAPEX / FCF (%) | 47.69% | 97.3% | 105.37% | 71.16% | 116.27% | 85.29% | 69.8% | 76.22% |
Items per share | ||||||||
Cash flow per share 1 | 8.36 | 4.991 | 5.18 | 7.22 | 5.209 | 6.782 | 8.224 | 8.218 |
Change | - | -40.3% | 3.79% | 39.38% | -27.86% | 30.21% | 21.25% | -0.06% |
Dividend per Share 1 | 2.8 | 2 | 2 | 2.4 | 0.11 | 0.1103 | 0.1103 | 1.118 |
Change | - | -28.57% | 0% | 20% | -95.42% | 0.24% | 0.01% | 913.73% |
Book Value Per Share 1 | 48.18 | 31.07 | 33.61 | 39.47 | 33.52 | 35.22 | 38.84 | 42.37 |
Change | - | -35.52% | 8.18% | 17.42% | -15.08% | 5.09% | 10.28% | 9.07% |
EPS 1 | 4.17 | -10.68 | 1.02 | 4.22 | -2.99 | 2.373 | 3.032 | 3.4 |
Change | - | -356.12% | -109.55% | 313.73% | -170.85% | -179.35% | 27.77% | 12.16% |
Nbr of stocks (in thousands) | 9,82,424 | 9,82,424 | 9,82,424 | 9,82,424 | 9,82,424 | 9,82,424 | 9,82,424 | 9,82,424 |
Announcement Date | 27/02/20 | 25/02/21 | 01/03/22 | 28/02/23 | 05/03/24 | - | - | - |
2024 * | 2025 * | |
---|---|---|
P/E ratio | 12.2x | 9.54x |
PBR | 0.82x | 0.74x |
EV / Sales | 1.32x | 1.23x |
Yield | 0.38% | 0.38% |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
- Stock Market
- Equities
- BAYN Stock
- Financials Bayer AG
MarketScreener is also available in this country: United States.
Switch edition